← All trials
NCT01561586
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Mar 1, 2017
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 590
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Korea Cancer Center HospitalLead sponsor
- Mahidol UniversityOverall official - principal investigator
- Yonsei UniversityCollaborator
- Seoul National UniversityCollaborator
- Korea Cancer Center HospitalReponsible party - principal investigator
- University of UlsanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.